Successful ruxolitinib administration for a patient with steroid-refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review.

Dan Tomomasa,Takeshi Isoda,Noriko Mitsuiki,Motoi Yamashita,Aoi Morishita,Takahiro Tomoda,Tsubasa Okano,Akifumi Endo,Takahiro Kamiya,Masakatsu Yanagimachi,Kohsuke Imai,Hirokazu Kanegane,Masatoshi Takagi,Tomohiro Morio

Clinical case reports（2021）

引用 5|浏览7

暂无评分

摘要

Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT-related IPS.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要